This aspect underscores the need for deeper investigation into the interactions between TGF-β-producing tumor-infiltrating T cells and other T cell subsets, particularly those sensitive to ICB, to uncover novel therapeutic targets. The gene discussed is TGFB1; the disease is neoplasm.